These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 23978126)

  • 1. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
    Singh AP; Shah DK
    AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
    Thudium K; Bilic S; Leipold D; Mallet W; Kaur S; Meibohm B; Erickson H; Tibbitts J; Zhao H; Gupta M
    MAbs; 2013; 5(1):5-12. PubMed ID: 23255090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
    Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
    J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
    Janthur WD; Cantoni N; Mamot C
    Int J Mol Sci; 2012 Nov; 13(12):16020-45. PubMed ID: 23443108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enthusiasm for antibody-drug conjugates.
    Tuma RS
    J Natl Cancer Inst; 2011 Oct; 103(20):1493-4. PubMed ID: 21972230
    [No Abstract]   [Full Text] [Related]  

  • 13. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
    Ait-Oudhia S; Zhang W; Mager DE
    AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.
    Dere R; Yi JH; Lei C; Saad OM; Huang C; Li Y; Baudys J; Kaur S
    Bioanalysis; 2013 May; 5(9):1025-40. PubMed ID: 23641694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.